Cerep assay panel
Eurofins Discovery has supported Drug Discovery research for over 40 years. We are recognized as the industry leader for providing drug discovery researchers the largest and most diverse portfolio of standard and custom in vitro safety& pharmacology assays and panels for drug screening and profiling.panel to enable early identification of significant offtarget interactions with your compound. All 44 selected targets, recommended by 4 major pharmaceutical companies (Bowes et al. 2012), are gathered in a costeffective panel that brings together both robustness (each assay is HTScompatible) and the strategic choice of informationrich targets. cerep assay panel
Eurofins Cerep was founded in December 1989 in Poitiers, France, as a service company to provide solutions for in vitro drug profiling and drug screening in pharmacology, allowing faster and costeffective drug discovery by identifying at early stages the most promising drug candidates, as well as eliminating those compounds likely to fail in development.
The targets in our SafetyScreen44 Panels are all strongly associated with in vivo adverse effects. This Safety Panel includes both enzymatic and binding assays. Aug 01, 2012 Offtarget screening (usually a CEREP panel) was performed by most companies early in preclinical development. As might be expected to slow the burn, smaller companies ran fewer preclinical screens to predict drug safety and performed these screens later in the drug development process.cerep assay panel Apr 15, 2013 Assay Overview: The purpose of this panel of binding assays performed by CEREP is to identify a subset of potential receptors, transporters, ion channels, etc. for which a lead OPRK1 antagonist compound displays affinity. Assays were run in duplicate.
Cerep assay panel free